Early and sustained deep molecular response achieved with nilotinib in high Sokal risk chronic myeloid leukemia patients

BACKGROUND: Nilotinib (Tasigna®) is a second-generation tyrosine kinase inhibitor that shows faster and deeper molecular responses (MR) in comparison to Imatinib as initial therapy in chronic phase chronic myeloid leukemia (CML). Efficacy and safety data for nilotinib in the Asian population is scar...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Manag Res
Auteurs principaux: Zaidi, Uzma, Kaleem, Bushra, Borhany, Munira, Maqsood, Sidra, Fatima, Naveena, Sufaida, Gul, Ansari, Saqib Hussain, Farzana, Tasneem, Shamsi, Tahir Sultan
Format: Artigo
Langue:Inglês
Publié: Dove Medical Press 2019
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6388993/
https://ncbi.nlm.nih.gov/pubmed/30863159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S181911
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires